Literature DB >> 22522622

Increasing scientific standards, independence and transparency in post-authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.

Kevin V Blake1, Corinne S Devries, Peter Arlett, Xavier Kurz, Henry Fitt.   

Abstract

PURPOSE: The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), an initiative coordinated by the European Medicines Agency, aims to build capacity for and increase trust in post-authorisation studies to further support medicine decision making.
METHODS: ENCePP seeks to promote and support high standards throughout the post-authorisation research process based on robust methodologies, transparency and scientific independence.
RESULTS: ENCePP provides a point of access to researchers for industry, academia and regulatory authorities seeking collaboration for the conduct of post-authorisation studies. As of 30 November 2011, the network consisted of 98 research centres, 13 networks and 18 data sources, mostly academic and publicly funded institutions but also data source providers and contract research organisations with expertise in the conduct of post-authorisation studies. All are listed in the free, public and fully searchable electronic Database of Research Resources. A guide and a checklist on methodological standards have been published; the concept of an 'ENCePP study', including a Code of Conduct, introduced; and an electronic register of studies have been launched.
CONCLUSION: It is envisaged that application of the ENCePP study concept will result in an increase in trust in post-authorisation studies of medicines. The register of studies will allow for ready access to study protocols and results, thereby enhancing transparency and facilitating review. Through the network, standards, transparency and clarity of relationships, ENCePP is expected to add to the European Union capacity to conduct robust post-authorisation studies, thereby benefiting public health.
Copyright © 2012 John Wiley & Sons, Ltd. Copyright © 2012 John Wiley & Sons, Ltd.

Year:  2012        PMID: 22522622     DOI: 10.1002/pds.3281

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  11 in total

1.  Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight.

Authors:  Pierre Engel; Mariana Ferreira Almas; Marieke Louise De Bruin; Kathryn Starzyk; Stella Blackburn; Nancy Ann Dreyer
Journal:  Br J Clin Pharmacol       Date:  2016-12-07       Impact factor: 4.335

2.  From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging Sources.

Authors:  Gianluca Trifirò; Janet Sultana; Andrew Bate
Journal:  Drug Saf       Date:  2018-02       Impact factor: 5.606

3.  Psychotropic medicine prescriptions in Italian youths: a multiregional study.

Authors:  Daniele Piovani; Antonio Clavenna; Massimo Cartabia; Maurizio Bonati
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-05-28       Impact factor: 4.785

4.  Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).

Authors:  Xavier Kurz; Susana Perez-Gutthann
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-01-11       Impact factor: 2.890

Review 5.  The ENCePP Code of Conduct: A best practise for scientific independence and transparency in noninterventional postauthorisation studies.

Authors:  Rosa Gini; Xavier Fournie; Helen Dolk; Xavier Kurz; Patrice Verpillat; François Simondon; Valerie Strassmann; Kathi Apostolidis; Thomas Goedecke
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-03-05       Impact factor: 2.890

Review 6.  Propensity Score Methods in Health Technology Assessment: Principles, Extended Applications, and Recent Advances.

Authors:  M Sanni Ali; Daniel Prieto-Alhambra; Luciane Cruz Lopes; Dandara Ramos; Nivea Bispo; Maria Y Ichihara; Julia M Pescarini; Elizabeth Williamson; Rosemeire L Fiaccone; Mauricio L Barreto; Liam Smeeth
Journal:  Front Pharmacol       Date:  2019-09-18       Impact factor: 5.810

7.  Pharmacogenetics and Depression: A Critical Perspective.

Authors:  Filippo Corponi; Chiara Fabbri; Alessandro Serretti
Journal:  Psychiatry Investig       Date:  2019-08-29       Impact factor: 2.505

8.  Drug Adverse Event Detection in Health Plan Data Using the Gamma Poisson Shrinker and Comparison to the Tree-based Scan Statistic.

Authors:  Jeffrey S Brown; Kenneth R Petronis; Andrew Bate; Fang Zhang; Inna Dashevsky; Martin Kulldorff; Taliser R Avery; Robert L Davis; K Arnold Chan; Susan E Andrade; Denise Boudreau; Margaret J Gunter; Lisa Herrinton; Pamala A Pawloski; Marsha A Raebel; Douglas Roblin; David Smith; Robert Reynolds
Journal:  Pharmaceutics       Date:  2013-03-14       Impact factor: 6.321

9.  Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK.

Authors:  Jaco Voorham; Nicolas Roche; Hicham Benhaddi; Marianka van der Tol; Victoria Carter; Job F M van Boven; Leif Bjermer; Marc Miravitlles; David B Price
Journal:  BMJ Open       Date:  2018-10-27       Impact factor: 2.692

10.  Incidence, risk factors and re-exacerbation rate of severe asthma exacerbations in a multinational, multidatabase pediatric cohort study.

Authors:  Marjolein Engelkes; Esme J Baan; Maria A J de Ridder; Elisabeth Svensson; Daniel Prieto-Alhambra; Francesco Lapi; Carlo Giaquinto; Gino Picelli; Nada Boudiaf; Frank Albers; Lee A Evitt; Sarah Cockle; Eric Bradford; Melissa K Van Dyke; Robert Suruki; Peter Rijnbeek; Miriam C J M Sturkenboom; Hettie M Janssens; Katia M C Verhamme
Journal:  Pediatr Allergy Immunol       Date:  2020-03-20       Impact factor: 6.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.